

Batten Disease Treatment Market, 2012 to 2023

<https://marketpublishers.com/r/B4E0759F917EN.html>

Date: December 2017

Pages: 204

Price: US\$ 4,400.00 (Single User License)

ID: B4E0759F917EN

Abstracts

Batten disease treatment market: Batten disease is most common group of disorders called Neuronal Ceroid Lipofuscinoses (NCLs). Batten disease is a rare, fatal and inherited nervous system disorder that generally begins in childhood. It is also caused by lysosome shortage. The symptoms in initial stages will be vision loss in previously healthy children followed by slow learning, personality and behavioural changes. Commonly within 2-4 years of vision loss seizures may appear. Generally, neuronal ceroid lipofuscinoses are classified into infantile NCL (INCL), late infant NCL (LINCL), juvenile NCL (JNCL) and adult NCL.

Market Outline: Global Batten disease Treatment

Batten disease treatment market is driven by an increase in R&D activities for development of new treatments for batten disease. In addition, lack of effective treatment options and increase in prevalence rates of batten disease treatment market are expected to boost the market growth over the forecast period. Furthermore, recent drug launches and growing awareness related to symptoms of disease are anticipated to bolster the batten disease treatment market during the forecast period. However, high cost of drug development, unavailability of many treatments for batten disease and a low number of patients are expected to hamper the market growth over the forecast period.

Global Batten disease Treatment market is segmented based on type of disease, treatment and distribution channel

Based on type of disease, batten disease treatment is segmented into

Juvenile NCL (JNCL)

Infantile NCL (INCL)

Late infant NCL (LINCL)

Adult NCL

Others

Based on treatment, batten disease treatment market is segmented into

Gene Therapy

Drug Therapy

Enzyme Therapy

Others

Based on distribution channel, batten disease treatment market is segmented into

Hospital Pharmacies

Retail Pharmacies

Others

According to National Institute of Neurological Disorders and Stroke, Batten disease occurs in an estimated 2 to 4 of every 100,000 live birth in U.S., and it is more common in Sweden, Finland, other parts of Northern Europe, and Newfoundland, Canada. Batten disease treatment market is still in development stage. Companies are adopting licencing and collaborations to increase market share. For instance, In June 2015, Abeona Therapeutics, Inc. (formerly PlasmaTech Biopharmaceuticals, Inc.) got worldwide exclusive rights to an AAV gene therapy for treatment of juvenile batten disease from UNeMed Corporation, a technology transfer company. In addition, many of the research and educational institutions focused on the development of new treatments for batten disease. Furthermore, government and non-government organizations such as Batten Disease Support and Research Association, Beyond The Batten Disease Foundation and others are actively participating in increasing the awareness about the batten disease and further expected to boost the growth of market.

Geographically, batten disease treatment market has been segmented into Latin America, Europe, Asia-Pacific, North America, and the Middle East & Africa. North America and Europe batten disease treatment market growth is attributed to increasing in R&D expenditure, growing awareness related to the batten disease due to various awareness programs being taken by the non-government and government organizations in the region. Furthermore, well-established infrastructure and recent drug launches are expected to boost the market in the U.S. region. Asia Pacific region market is expected to offer lucrative growth due to lower R&D costs, developing healthcare infrastructure and growing prevalence rates of genetic disorders.

Some of the players in batten disease treatment market are Abeona Therapeutics Inc. (U.S.), BioMarin Pharmaceutical Inc. (U.S.), CereSpir Inc. (U.S.), Evotec AG (Germany), Ionis Pharmaceuticals Inc. (U.S.), Mitochon Pharmaceuticals Inc. (U.S.), and Spark Therapeutics Inc. (U.S.) to name a few.

In April 2017, U.S. FDA has approved BioMarin Pharmaceutical Inc.'s Brineura, the first FDA approved treatment for a form of batten disease

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL BATTEN DISEASE TREATMENT MARKET INTRODUCTION

2.1. Global Batten Disease Treatment Market – Taxonomy

2.2. Global Batten Disease Treatment Market –Definitions

2.2.1. Disease Type

2.2.2. Distribution Channel

3. GLOBAL BATTEN DISEASE TREATMENT MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Batten Disease Treatment Market Dynamics – Factors Impact Analysis

3.6. Global Batten Disease Treatment Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. Global Batten Disease Treatment Market – Product Innovations

4. GLOBAL BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL BATTEN DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Disease Type Analysis (2012-2016) and Forecast (2017-2023) by Revenue (USD Mn) and Y-o-Y Growth (%)

5.1.1. Juvenile NCL (JNCL)

5.1.2. Infantile NCL (INCL)

- 5.1.3. Late infant NCL (LINCL)
- 5.1.4. Adult NCL
- 5.1.5. Others
- 5.1.6. Market Opportunity Analysis

6. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. Gene Therapy
- 6.2. Drug Therapy
- 6.3. Enzyme Therapy
- 6.4. Others
- 6.5. Market Opportunity Analysis

7. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

- 7.1. Hospital Pharmacies
 - 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.1.3. Market Opportunity Analysis
- 7.2. Retail Pharmacies
 - 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.2.3. Market Opportunity Analysis
- 7.3. Others
 - 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.3.3. Market Opportunity Analysis

8. GLOBAL BATTEN DISEASE TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

- 8.1. North America
 - 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 8.1.3. Market Opportunity Analysis
- 8.2. Europe
 - 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.3.3. Market Opportunity Analysis

8.4. Latin America

8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

8.5.3. Market Opportunity Analysis

8.6. Global Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Diseases Type, Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Juvenile NCL (JNCL)

9.1.1.2. Infantile NCL (INCL)

9.1.1.3. Late infant NCL (LINCL)

9.1.1.4. Adult NCL

9.1.1.5. Others

9.1.1.6. Market Opportunity Analysis

9.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. Gene Therapy

9.1.2.2. Drug Therapy

9.1.2.3. Enzyme Therapy

9.1.2.4. Others

9.1.2.5. Market Opportunity Analysis

9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospital Pharmacies

9.1.3.2. Retail Pharmacies

9.1.3.3. Others

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Disease Type, Distribution Channel and Country, 2017 – 2023

9.1.6. North America Batten Disease Treatment Market Dynamics – Trends

10. EUROPE BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Juvenile NCL (JNCL)

10.1.1.2. Infantile NCL (INCL)

10.1.1.3. Late infant NCL (LINCL)

10.1.1.4. Adult NCL

10.1.1.5. Others

10.1.1.6. Market Opportunity Analysis

10.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. Gene Therapy

10.1.2.2. Drug Therapy

10.1.2.3. Enzyme Therapy

10.1.2.4. Others

10.1.2.5. Market Opportunity Analysis

10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospital Pharmacies

10.1.3.2. Retail Pharmacies

10.1.3.3. Others

10.1.3.4. Market Opportunity Analysis

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023

10.1.6. Europe Batten Disease Treatment Market Dynamics – Trends

11. ASIA-PACIFIC BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Juvenile NCL (JNCL)

11.1.1.2. Infantile NCL (INCL)

11.1.1.3. Late infant NCL (LINCL)

11.1.1.4. Adult NCL

11.1.1.5. Others

11.1.1.6. Market Opportunity Analysis

11.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. Gene Therapy

11.1.2.2. Drug Therapy

11.1.2.3. Enzyme Therapy

11.1.2.4. Others

11.1.2.5. Market Opportunity Analysis

11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Hospital Pharmacies

11.1.3.2. Retail Pharmacies

11.1.3.3. Others

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023

11.1.6. Europe Batten Disease Treatment Market Dynamics – Trends

12. LATIN AMERICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Juvenile NCL (JNCL)

12.1.1.2. Infantile NCL (INCL)

12.1.1.3. Late infant NCL (LINCL)

12.1.1.4. Adult NCL

12.1.1.5. Others

12.1.1.6. Market Opportunity Analysis

12.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. Gene Therapy

12.1.2.2. Drug Therapy

12.1.2.3. Enzyme Therapy

12.1.2.4. Others

12.1.2.5. Market Opportunity Analysis

12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospital Pharmacies

12.1.3.2. Retail Pharmacies

12.1.3.3. Others

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023

12.1.6. Latin America Batten Disease Treatment Market Dynamics – Trends

13. MIDDLE EAST AND AFRICA BATTEN DISEASE TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Disease Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Juvenile NCL (JNCL)

13.1.1.2. Infantile NCL (INCL)

13.1.1.3. Late infant NCL (LINCL)

13.1.1.4. Adult NCL

13.1.1.5. Others

13.1.1.6. Market Opportunity Analysis

13.1.2. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. Gene Therapy

13.1.2.2. Drug Therapy

13.1.2.3. Enzyme Therapy

13.1.2.4. Others

13.1.2.5. Market Opportunity Analysis

13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Hospital Pharmacies

13.1.3.2. Retail Pharmacies

13.1.3.3. Others

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Batten Disease Treatment Market - Opportunity Analysis Index, By Disease Type, Distribution Channel, and Country, 2017 – 2023

13.1.6. MEA Batten Disease Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. Abeona Therapeutics Inc. (U.S.)

14.2.2. BioMarin Pharmaceutical Inc. (U.S.)

14.2.3. CereSpir Inc. (U.S.)

14.2.4. Evotec AG (Germany)

14.2.5. Ionis Pharmaceuticals Inc. (U.S.)

14.2.6. Mitochon Pharmaceuticals Inc. (U.S.)

14.2.7. Spark Therapeutics Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Batten Disease Treatment Market, 2012 to 2023

Product link: <https://marketpublishers.com/r/B4E0759F917EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B4E0759F917EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970